Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Vaclav Ranc | Palacký University in Olomouc | Czech Republic

Dr. Václav Ranc is a distinguished analytical chemist and data analyst with over 15 years of experience in academia and applied research. Based in the Czech Republic, he leads a research group at Palacký University Olomouc, specializing in nanotechnology, plasmonic and electronic nanosensors, and advanced analytical techniques. He holds a Ph.D. in Analytical Chemistry and a Habilitation in Physical Chemistry. Dr. Ranc has published over 80 peer-reviewed scientific articles and holds several international patents. He has secured and managed significant EU funding, including Horizon Europe and MSCA projects, showcasing his excellence in both research and project leadership. His expertise spans Raman spectroscopy, mass spectrometry, and LC/GC methods, coupled with data analysis in Python, Matlab, and R. He is a regular presenter at international conferences and a recognized innovator in the fields of biosensing and nanomaterials.

Publication Profiles: 

Google Scholar
Orcid
Scopus

Education:

Dr. Václav Ranc earned his MSc. in Analytical Chemistry from Palacký University Olomouc (UPOL) in 2005, where he focused on the discrimination of enantiomers using mass spectrometry techniques such as LC-MS and CE-MS. He continued at UPOL to complete his Ph.D. in Analytical Chemistry, specializing in chiral analysis with HPLC-MS and GC-MS. His academic trajectory culminated in a Habilitation in Physical Chemistry, reflecting his advancements in Raman microscopy, SERS, and mass spectrometry. Dr. Ranc’s education is deeply rooted in analytical and physical chemistry, with a significant emphasis on developing and applying sophisticated separation and detection techniques for complex biological and clinical samples. His academic background is further enriched by international research experiences in Sweden and Switzerland, where he worked on electroanalytical techniques and nanoLC-MS applications for neurotransmitter analysis.

Experience:

Dr. Václav Ranc currently serves as the Head of a Research Group at Palacký University Olomouc, managing a 20-member team focused on cutting-edge nanomaterials and analytical chemistry. He has led the group’s scientific, financial, and personnel management, improving research output by 30%. Previously, he worked as a Research Assistant in Switzerland and at Palacký University, where he developed analytical techniques for clinical and neurological studies using mass spectrometry. His earlier roles include assisting in electrochemical method development at Lund University and clinical toxicology at Faculty Hospital Olomouc. His leadership extends to managing multimillion-CZK budgets and delivering impactful results in EU-funded research projects. Throughout his career, he has seamlessly combined academic excellence with innovation, leading to patented technologies and industrial prototypes, while mentoring young researchers and collaborating with international scientific networks.

Honors & Awards:

Dr. Václav Ranc has received several national and international honors for his scientific excellence. Notable among them is the Golden Medal at the International Invent Arena for the innovative KeyLock authentication system. He also earned the Bronze Prize from MERCK’s Young Analytical Chemists Competition and was a Finalist for the prestigious Shimadzu Prize for Young Analytical Chemists. His awards reflect consistent recognition for his groundbreaking work in analytical chemistry and applied nanotechnology. These accolades underscore his ability to translate complex research into practical applications, particularly in biosensing, authentication systems, and advanced materials. Dr. Ranc’s career is marked by impactful innovations that bridge academic research with industry needs, affirming his role as a thought leader in his field. His awarded projects and patents have contributed significantly to medical diagnostics, material sciences, and anti-counterfeiting technologies.

Research Focus:

Dr. Ranc’s research focuses on analytical chemistry, nanotechnology, and biosensing. He specializes in Raman spectroscopy (including SERS), LC/GC-MS, and the development of plasmonic and electronic nanosensors. His work bridges basic science and applied innovation, emphasizing the synthesis of nanoparticles, development of authenticity verification systems, and detection of biomarkers in clinical diagnostics. His contributions to surface-enhanced Raman spectroscopy have led to the development of patented methods and tools, including test strips and analytical systems. Dr. Ranc’s interdisciplinary approach combines analytical method development, data analysis using Python, R, and Matlab, and project management of EU-funded research. His current Horizon Europe projects focus on medical applications of nanotechnology, contributing to improved diagnostics, drug delivery systems, and authenticity verification. Through collaborations with European research institutions and industries, Dr. Ranc is pushing the boundaries of next-gen biomedical and analytical technologies.

Publication Top Notes:

  1. Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy

  2. Highly Cytotoxic Copper(II) Mixed-Ligand Quinolinonato Complexes: Pharmacokinetic Properties and Interactions with Drug Metabolizing Cytochromes P450

  3. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy

  4. Polymer-Based Graphene Derivatives and Microwave-Assisted Silver Nanoparticles Decoration as a Potential Antibacterial Agent

  5. New Limits for Stability of Supercapacitor Electrode Material Based on Graphene Derivative

  6. Label-free Determination of Prostate Specific Membrane Antigen in Human Whole Blood by Magnetically Assisted SERS

  7. Cyanographene and Graphene Acid: Emerging Derivatives Enabling High-Yield and Selective Functionalization of Graphene

  8. Detection of Prosthetic Joint Infection Based on Magnetically Assisted Surface Enhanced Raman Spectroscopy

  9. Functional Nanosheet Synthons by Covalent Modification of Transition-Metal Dichalcogenides

  10.  Nanoporous Nitrogen-Doped Graphene Oxide/Nickel Sulfide Composite Sheets for Hydrogen and Oxygen Evolution

Conclusion:

In conclusion, Dr. Václav Ranc is an exceptional candidate for the Best Researcher Award, demonstrating a rare synergy of academic excellence, applied innovation, and impactful leadership. His contributions to analytical chemistry and nanotechnology have advanced both scientific understanding and practical diagnostic solutions. His impressive publication record, international collaborations, patent portfolio, and success in leading multimillion-euro projects set him apart as a researcher of outstanding merit. With minor expansion into global research programs and commercialization efforts, Dr. Ranc is poised to further amplify his already significant impact. For his sustained contributions to science, his ability to lead and innovate, and his commitment to solving real-world problems through chemistry and nanotechnology, Dr. Václav Ranc is highly deserving of the Best Researcher Award.

Dominique Heymann | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Dominique Heymann | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Dominique Heymann , Nantes Université, CNRS, Institut de Cancérologie de l”Ouest , France

Professor Dominique Heymann is a highly esteemed academic and clinician, specializing in histology, embryology, and oncology. He is a Professor at Nantes University, France, and a Hospital Practitioner at the ICO Cancer Centre. With a wealth of experience in bone oncology and cancer research, he is also an Honorary Professor at the University of Sheffield, UK. His expertise spans from cell biology to immunology and biochemistry, and he is dedicated to advancing cancer research, particularly in the field of bone tumors and osteosarcoma. With numerous publications to his name and contributions to the global scientific community, Professor Heymann is recognized for his groundbreaking work in cell signaling and tumor progression. He is a valued researcher in the oncology community, with a strong focus on developing innovative therapies for cancer treatment.

Publication Profile:

Google Scholar

Strengths for the Award:

Professor Dominique Heymann is a distinguished figure in the field of oncology, particularly bone oncology, with a strong focus on the molecular mechanisms of bone tumors like osteosarcoma. His academic and clinical roles at the University of Nantes and the ICO Cancer Centre underscore his leadership in research and patient care. He has contributed significantly to understanding tumor biology, bone remodeling, and regenerative medicine, making him a highly respected expert in these fields. His research addresses crucial topics such as circulating tumor cells, targeted therapies, and the development of new anticancer agents, all of which are of immense value to advancing cancer treatment. With multiple publications in prestigious journals, including studies on novel therapies and molecular pathways in cancer progression, Professor Heymann has demonstrated exceptional scientific rigor. His global collaborations and recognition further establish him as a leading researcher in cancer biology and oncology.

Areas for Improvements:

Despite his numerous contributions, there are a few areas where Professor Heymann’s research could evolve. While he has made notable strides in cancer treatment and bone oncology, expanding research into more personalized medicine approaches and exploring the integration of AI and machine learning in predictive oncology could enhance the applicability of his findings. Furthermore, increasing collaborative efforts with international interdisciplinary teams could yield broader insights, especially in rare cancers and metastasis research. Developing a more extensive outreach to clinical trials and collaborations in broader regions may also allow for faster translation of his research into practice.

Education:

Professor Heymann began his academic journey at Paris VII University, where he earned a Master’s degree in Cell Biology in 1991. His PhD in Cell Biology and Immunology was completed at Nantes University in 1995, a pivotal moment in his career. Further expanding his knowledge, he pursued research management abilities and a deeper focus on Biochemistry and Cell Biology at Nantes University in 1998. He also received specialized certification in Histology from Nantes University in 1999 and later completed the required authorizations for animal experimentation in 2003 and 2016. Throughout his academic career, Professor Heymann has continually updated his qualifications, ensuring his expertise remains at the cutting edge of medical and biological sciences. His academic foundation has underpinned his significant contributions to cancer research, with a strong emphasis on bone oncology and regenerative medicine.

Experience:

Professor Dominique Heymann has an extensive and diverse career spanning several decades in both academic and clinical settings. Currently, he serves as a Professor of Histology/Embryology at Nantes University and as a Hospital Practitioner at the ICO Cancer Centre, where he is instrumental in patient care and research. His professional trajectory includes significant roles in oncology, particularly focused on bone tumors, osteosarcoma, and regenerative medicine. As an Honorary Professor at the University of Sheffield, he extends his influence beyond France, fostering international collaboration in cancer research. Professor Heymann has been a prominent figure in multiple research projects, having managed and contributed to groundbreaking studies. His expertise in cancer biology, combined with his academic roles, has allowed him to mentor students and researchers, shaping the next generation of scientists. His dual role in academia and clinical practice makes him a leading figure in both spheres.

Awards and Honors:

Professor Dominique Heymann’s career is adorned with numerous accolades and honors. As a tenured professor at the University of Nantes, he has received recognition for his contributions to histology, embryology, and oncology. He was appointed as an Honorary Professor in Bone Oncology at the University of Sheffield, UK, an esteemed acknowledgment of his expertise in the field. His work in cancer research, particularly related to bone tumors, has earned him international recognition, and his published studies continue to be highly regarded in scientific journals. Additionally, Professor Heymann has contributed significantly to the understanding of osteosarcoma and bone regeneration, which has earned him awards from academic and clinical societies. His continuous impact in advancing the field through groundbreaking research, leadership in clinical oncology, and educational contributions has made him a highly respected figure in the medical and scientific communities.

Research Focus:

Professor Dominique Heymann’s research is focused on cancer, particularly bone tumors such as osteosarcoma, and the molecular mechanisms involved in bone regeneration. His work primarily investigates the signaling pathways that control bone remodeling, the interactions between tumor cells and the microenvironment, and the role of immune responses in bone diseases. One of his key research interests is the development of targeted therapies to combat cancer progression, with a special emphasis on novel anticancer agents, including glycosaminoglycan-mimetic compounds derived from marine bacterial exopolysaccharides. In addition, Professor Heymann is dedicated to studying the role of circulating tumor cells as predictive markers for drug resistance and tumor progression. His expertise also includes stem cell therapies, autophagy in osteoblasts, and the potential for therapeutic applications in bone repair and regeneration. His research aims to improve patient outcomes through innovative approaches in cancer treatment and bone health.

Publications Top Notes:

  • Heymann D, Muñoz-Garcia J, Babuty A, et al. A new promising anticancer agent: a glycosaminoglycan-mimetic derived from the marine bacterial infernan exopolysaccharide. Int J Biol Macromol. (in press) 🧬

  • Jacquot P, Muñoz-Garcia J, Léger A, et al. A multispecific checkpoint inhibitor Nanofitin with a fast tumor accumulation property and antitumor activity in immune competent mice. Biomolecules. (in press) 🔬

  • Yadav P, Heymann D, Prasad RN. Circulating tumor cells: a predictive marker for drug resistance and tumor progression. Front Oncol. (in press) 🔬

  • Muñoz-Garcia J, et al. Interleukin-34 orchestrates bone formation through its binding to Bone Morphogenic Proteins. Theranostics. 2025; 15(7):3185-3202. 🦴

  • Young RJ, et al. CIRCUS: CIRCUlating tumor cells in soft tissue Sarcoma – a short report. Cancer Drug Resist. 2022; 4:51. 💉

  • Oliver L, et al. Transcriptional landscape of the interaction of human mesenchymal stem cells with glioblastoma in bioprinted co-cultures. Stem Cell Res Ther. 2024; 15(1):424. 🧫

  • Cordova LA, et al. Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care? Osteoporos Int. 2024; 35(9):1677-1678. 🦷

  • Childs A, et al. A prospective observational cohort study for newly diagnosed patients in the UK: ICONIC study initial results. Cancers (Basel). 2024; 16(13):2351. 📊

  • Rey V, et al. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBioMedicine. 2024; 102:105090. 🧬

  • Jubelin C, et al. Identification of MCM4 and PKRDC as new regulators of osteosarcoma cell dormancy based on 3D cultures. BBA Mol Cell Res. 2024; 1871:119660. 🧪

Conclusion:

Professor Dominique Heymann’s expertise in oncology, histology, and embryology positions him as an outstanding candidate for the Research for Best Researcher Award. His achievements in cancer research, particularly in bone tumors, and his contributions to advancing the understanding of tumor biology make him an exemplary figure. While there are areas to expand in terms of interdisciplinary collaborations and technological integration, his exceptional body of work and his dedication to both academic excellence and clinical practice make him a deserving candidate for this prestigious award.

Arunima Biswas | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Arunima Biswas | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Arunima Biswas , university of kalyani , India

Dr. Arunima Biswas is an Assistant Professor in the Department of Zoology at the University of Kalyani, India. With a Ph.D. in Biochemistry from the Indian Institute of Chemical Biology, Kolkata, she has focused her career on understanding the molecular mechanisms underlying diseases, particularly cancer and parasitic infections. She leads multiple funded research projects, aiming to develop targeted therapies for various cancers. Dr. Biswas has worked extensively on the cyclic nucleotide signaling pathways in unicellular eukaryotes like Leishmania and cancer. A passionate educator and researcher, she mentors Ph.D. students and collaborates with international scientists to advance medical research.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Arunima Biswas demonstrates significant contributions to cancer research and parasitology. She is highly skilled in understanding and manipulating cyclic nucleotide signaling pathways, which play a crucial role in cancer biology and parasitic diseases like Leishmania infections. With several ongoing research projects, including the repurposing of phosphodiesterase inhibitors for cancer therapy and the development of targeted drug delivery systems, Dr. Biswas has shown an innovative approach to solving complex medical challenges. Her leadership as Principal Investigator for high-impact projects, such as cancer screening and drug targeting, highlights her as a leading researcher in her field. Furthermore, her dedication to mentoring and producing highly qualified Ph.D. students is commendable.

Areas for Improvement:

While Dr. Biswas’ research is already impactful, expanding her work on the practical clinical application of her findings could further bridge the gap between research and patient care. Collaboration with clinical trials or hospitals could expedite the translation of her findings into therapeutic solutions. Additionally, expanding interdisciplinary collaborations could bring novel insights into her research.

Education:

Dr. Arunima Biswas earned her Ph.D. in Biochemistry from the Indian Institute of Chemical Biology, Kolkata, with a thesis on Host-parasite interaction: Modulation of signaling pathways in Macrophage and Leishmania (2010). Prior to this, she completed her Master of Science in Zoology from the University of Calcutta with First Class honors (2005). She also holds a Bachelor of Science in Zoology from Maulana Azad College, University of Calcutta (2003). Her academic journey has been marked by a strong foundation in biochemistry, signaling pathways, and parasitology, forming the basis of her current research interests.

Experience:

Dr. Arunima Biswas has over a decade of teaching and research experience. As an Assistant Professor at the University of Kalyani, she has significantly contributed to the academic and research growth in the Department of Zoology. She is the Principal Investigator of several research projects funded by national bodies like CSIR, SERB, and UGC, with an emphasis on cancer research, especially targeting pathways involving cyclic nucleotides. Dr. Biswas has also collaborated with multiple national and international institutions and mentored several Ph.D. students, contributing to their academic and research advancements. Her experience in guiding research and mentoring future scientists is widely acknowledged.

Awards and Honors:

Dr. Arunima Biswas has received numerous accolades for her research and academic contributions. Notably, she won the Young Scientist Presentation Award at the Translational Cancer Research Conference (2020) and was honored with an International Congress of Cell Biology Travel Award (2016). She also received the American Society of Biochemistry and Cell Biology Travel Award (2015) and the prestigious DST-INSPIRE Faculty Scheme award (2012). These recognitions underscore her outstanding contributions to biomedical research, particularly in cancer biology and parasitology, further establishing her as a leader in her field.

Research Focus:

Dr. Arunima Biswas’s research focuses on cancer biology and parasitology, particularly the role of cyclic nucleotide signaling in cancer and Leishmania infections. She investigates therapeutic targets to modulate these pathways for better treatment options in cancer, including breast and gynecological cancers. Her ongoing projects include exploring phosphodiesterase inhibitors for breast cancer and cervical cancer, as well as developing vesicular drug carriers for targeted drug delivery. Dr. Biswas is dedicated to understanding the molecular intricacies of host-parasite interactions and their implications for disease management.

Publications Top Notes:

  1. Metal Oxide–Enhanced Para-Coumaric Acid Nanoparticles for Precision Targeting of Leishmania donovani
  2. Repurposing Approved Protein Kinase Inhibitors as Potent Anti-Leishmanials Targeting Leishmania MAP Kinases
  3. Anticancer, Antimicrobial, and Photocatalytic Activities of a New Pyrazole-Containing Thiosemicarbazone Ligand and Its Co(III) and Ni(II) Complexes
  4. Synthesis, Spectroscopy, and Structural Elucidation of Two New CoII and NiII Complexes of Pyrazole Derived Heterocyclic Schiff Base Ligand as Potential Anticancer and Photocatalytic Agents
  5. Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity
  6. Rhodamine Hydrazide-Linked Naphthalimide Derivative: Selective Naked Eye Detection of Cu2+, S2− and Understanding the Therapeutic Potential of the Copper Complex as an Anti-Cervical Cancer Agent
  7. Modulation and Determination of the Status of Inflammasomes in Leishmania-Infected Macrophages
  8. Catalytic and Anticancer Activity of Two New Ni(II) Complexes with a Pyrazole-Based Heterocyclic Schiff-Base Ligand
  9. Biophysical Study on DNA and BSA Binding Activity of Cu(II) Complex: Synthesis, Molecular Docking, Cytotoxic Activity, and Theoretical Approach
  10. Cytotoxic Behavior and DNA/BSA Binding Activity of Thiosemicarbazone-Based Ni(II) Complex: Bio-Physical, Molecular Docking, and DFT Study

Conclusion:

Dr. Arunima Biswas is an exceptional candidate for the “Best Researcher Award.” Her diverse research in cancer biology, parasitology, and drug development showcases her commitment to advancing healthcare. She has made significant strides in understanding complex molecular mechanisms, and her work holds great promise for improving cancer treatments. With a robust academic record, influential publications, and ongoing impactful projects, Dr. Biswas is undoubtedly a deserving contender for the award.

 

 

 

Huining He | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Huining He | Cancer Cell Biology | Best Researcher Award

Prof. Huining He , School of Biomedical Engineering and Technology, Tianjin Medical University , China

Dr. Huining He is a prominent Professor and the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, China. With a Ph.D. in Chemical Engineering from Tianjin University, she completed joint research at the University of Michigan. Her career spans across significant achievements in biomedical engineering, specializing in biomaterials, drug delivery systems, and cancer therapy. She has been recognized with prestigious awards, including the “Young Changjiang Scholar” and the “Tianjin Science Fund for Outstanding Young Scholars.” As an active member of various academic societies and a board member of the Asian Journal of Pharmaceutical Sciences, she fosters international collaboration and academic advancement. Her research has garnered substantial contributions to the field of biomedical engineering, with numerous patents and high-impact publications in cancer treatment and drug delivery systems.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Huining He is an outstanding researcher with a strong academic and professional background. As a Professor and Dean at Tianjin Medical University, she leads the School of Biomedical Engineering and Technology with a focus on cutting-edge biomedical research, particularly in biomaterials and drug delivery systems. Her innovative work in the development of enzyme-sensitive targeted systems for gene therapy and prodrug-type macromolecular drug delivery for colon cancer is a key contribution to the field. Additionally, her leadership in several projects funded by the National Natural Science Foundation of China, particularly those targeting glioma treatment, showcases her ability to translate research into impactful clinical applications.

Dr. He’s collaboration with international and domestic institutions further enhances her research impact. She is well-regarded for pioneering novel drug delivery systems and has made notable contributions through numerous high-quality publications, which have earned her an H-index of 21 and six authorized patents. She also actively participates in academic exchanges and professional networks, serving as a member of editorial boards and scientific committees.

Areas for Improvements:

While Dr. He has made remarkable strides in biomedical engineering, there are areas where further focus could amplify her impact:

  1. Broader Clinical Application: The continued translation of her drug delivery systems into clinical settings could benefit from additional industry partnerships and clinical trials.
  2. Interdisciplinary Collaboration: Expanding her work to incorporate emerging fields such as artificial intelligence in drug delivery systems could lead to more personalized treatment solutions.
  3. Public Engagement: Increasing public awareness of her research through media and outreach could bridge the gap between academia and the general public, facilitating broader societal impact.

Education:

Dr. Huining He earned her Ph.D. in Chemical Engineering from Tianjin University, where she gained profound expertise in biomaterials and drug delivery systems. During her doctoral studies, she participated in joint training at the University of Michigan, an experience that greatly expanded her research skills and international perspective. This training allowed her to engage in cutting-edge projects in the fields of biomaterials and drug delivery. Her advanced education laid the foundation for her future contributions to biomedical engineering, especially in the development of novel targeted systems for gene therapy and cancer treatment. Dr. He’s academic journey has been marked by strong mentorship, international collaborations, and her leadership role in several research projects that have significantly advanced the biomedical field.

Experience:

Dr. Huining He’s career in biomedical engineering spans extensive academic and research experience. Currently, as the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, she leads a dynamic department focused on advancing healthcare solutions through innovative research. She has supervised numerous Ph.D. students, guiding them in pioneering research on biomaterials and drug delivery systems. Her work has been recognized by the Ministry of Education, with prestigious titles such as the “Young Changjiang Scholar.” Dr. He has led and contributed to several high-profile research projects funded by China’s National Natural Science Foundation, including investigations into enzyme-sensitive targeted systems for gene therapy and glioma treatment. Beyond academia, she has participated in industry projects, translating her research into real-world applications. As a member of numerous professional organizations and editorial boards, Dr. He plays a vital role in facilitating international collaborations and advancing scientific knowledge in the biomedical sector.

Research Focus:

Dr. Huining He’s research focuses on the design and development of advanced biomaterials and drug delivery systems, particularly in the treatment of cancer and other serious diseases. Her work involves creating innovative, targeted drug delivery systems that can enhance the efficacy and precision of treatment. She has conducted pivotal studies on enzyme-sensitive targeted systems for gene therapy, improving the delivery of therapeutic agents to cancer cells. Currently, Dr. He is leading several projects on siRNA co-delivery systems for glioma, investigating ways to overcome the challenges in glioma treatment. Her research also covers the development of prodrug-type macromolecular systems and multifunctional exosome-based drug delivery technologies. Dr. He’s work has the potential to revolutionize cancer treatment and other therapeutic approaches, contributing to the development of more efficient, less toxic therapies for patients. Her research continues to make substantial advancements in the fields of drug delivery, biomedical engineering, and cancer therapy.

Publications Top Notes:

  1. CaCO3-based nanomedicine with multi-functions of ferroptosis-apoptosis and microenvironment regulation in cancer 🔬💡 (Nano Today, 2025)
  2. Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation 🧬⚡ (ACS Nano, 2024)
  3. Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy 💊🧪 (Chinese Chemical Letters, 2024)
  4. A review on gold nanoparticles as an innovative therapeutic cue in bone tissue engineering: Prospects and future clinical applications 🏥🔬 (Materials Today Bio, 2024)
  5. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment 🧬🔗 (Journal of Controlled Release, 2024)
  6. An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma 💉🧠 (Acta Pharmaceutica Sinica B, 2023)
  7. Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles 🧬💥 (Acta Pharmaceutica Sinica B, 2023)
  8. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence 💧⚔ (Journal of Controlled Release, 2022)
  9. Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation 🧬💉 (Medicine in Drug Discovery, 2022)
  10. mRNA vaccines for COVID-19 and diverse diseases 💉🦠 (Journal of Controlled Release, 2022)

Conclusion:

Dr. Huining He’s exceptional contributions to the field of biomedical engineering, particularly in the development of novel drug delivery systems for cancer treatment, position her as an ideal candidate for the Best Researcher Award. Her innovative work, combined with a clear vision for the future of precision medicine, continues to drive the field forward. She has the potential to further revolutionize medical treatments, making her a deserving nominee for this prestigious recognition.